secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2026-10-06T20:31:30+00:00
Accession:  0001641489-26-000032
Event type: other_material
Sentiment:  neutral
Materiality: 0.12
Item codes: 5.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

vTv Therapeutics adopts Third Amended and Restated By-Laws with new nomination and forum rules
--------------------------------------------------------------------------------

- Board approved the Third Amended and Restated By-Laws on October 1, 2026; changes cover director nominations, voting standards, forum selection and DGCL conformity.
- Nominating stockholders must now deliver reasonable evidence of Rule 14a-19 compliance no later than five business days before the stockholder meeting.
- Voting standard revised: in all matters other than director elections, the affirmative vote of a majority of voting power cast affirmatively or negatively is the act of stockholders.
- Federal district courts designated as the exclusive forum for Securities Act of 1933 claims unless the Company consents in writing to an alternative forum.
- Amended By-Laws attached as Exhibit 3.1; 8-K signed by President and CEO Paul J. Sekhri and dated October 6, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148926000032/0001641489-26-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148926000032/vtvt-20261001.htm
  HTML page:      https://secwatch.observer/filing/0001641489-26-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer